Due to the regulatory effect of circPDHK1 on AKT-mTOR signaling pathway, we discovered that silencing circPDHK1 can partially enhance the anti-tumor efficacy and sensitivity of TKI drugs or AKT-mTOR inhibitors for ccRCC in vitro. Here, AKT1 is linked to neoplasm.